Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission

ASH 2019

Published: 10 Dec 2019

Views: 966

Rating:

Save

Prof Andrew Wei - Monash University, Melbourne, Australia

Prof Andrew Wei presents at ASH 2019, the primary findings from the QUAZAR AML-001 maintenance trial, which evaluated CC-486, an oral formulation of azacitidine as a maintenance therapy in older patients with acute myeloid leukaemia (AML) in first remission following intensive induction chemotherapy.

Watch our interview with Prof Wei here.

Read more about the study here.

Related Videos

Treatment management of favourable risk and very favourable risk patients

Dr Guillermo de Velasco and Dr Marco Maruzzo

Treatment management of favourable risk and very favourable risk patients ( Dr Guillermo de Velasco and Dr Marco Maruzzo )

Burden and trends of breast cancer worldwide: Opportunities for prevention?

Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi

Burden and trends of breast cancer worldwide: Opportunities for prevention? ( Dr Eileen Morgan, Dr Isabelle Soerjomataram and Dr Shalaka Joshi )

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

Dr Ricky Frazer and Dr Sree Subramanian

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective ( Dr Ricky Frazer and Dr Sree Subramanian )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC

Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC ( Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Multiple Myeloma: evolving paradigm - Panel Discussion

Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar

Multiple Myeloma: evolving paradigm - Panel Discussion ( Moderator: Dr Dibeyndu De/Panelists: Dr Amit Kumar, Dr Sunil Dharmani, Dr Siddharth Nanda AIIMS, Dr Avinash Tiwari, Dr Rudra Pratap, Dr Siddharth Turkar )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

More from ecancer